SMARCA4 and non-small cell lung carcinoma: Patients with advanced (stage 3B or IV) NSCLC harboring homozygous truncating SMARCA4 mutations had significantly worse median overall survival (mOS) compared to their wild‐type counterparts (7.9 vs. 16.3 months, hazard ratio [HR] 1.85) [19].